Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain CORT message board posts where the ticker symbol CORT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest CORT SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001225208-18-015870 Size: 7 KB
2018-11-26
8-K  Documents Current report, item 5.02
Acc-no: 0001193125-18-329608 (34 Act)  Size: 15 KB
2018-11-19 000-50679
181191340
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001225208-18-015527 Size: 14 KB
2018-11-14
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-028605 Size: 9 KB
2018-11-09
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-18-026315 (34 Act)  Size: 4 MB
2018-11-02 000-50679
181155012
8-K  Documents Current report, items 2.02, 7.01, and 9.01
Acc-no: 0001171843-18-007477 (34 Act)  Size: 111 KB
2018-11-01 000-50679
181153856
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-026440 Size: 9 KB
2018-10-09
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-024192 Size: 9 KB
2018-09-11
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001225208-18-012868 Size: 8 KB
2018-08-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-023082 Size: 5 KB
2018-08-22
More CORT SEC Filings


Related news from
Thu, 13 Dec 2018
13:35:49 +0000
Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome
Corcept Therapeutics Incorporated (CORT) announced today that the United States Patent and Trademark Office has given notice that it will allow a patent covering the concomitant use of Korlym® and drugs from the class of medications known as strong CYP3A inhibitors to treat patients with hypercortisolism (Cushing’s syndrome).  The patent will expire in 2037. “This patent covers an important finding of our research – that with proper dose modulation, Korlym can safely be administered in combination with medications that are strong CYP3A inhibitors,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.
Wed, 12 Dec 2018
11:50:00 +0000
Today's Research Reports on Trending Tickers: MYOS RENS Technology and Corcept Therapeutics
NEW YORK, NY / ACCESSWIRE / December 12, 2018 / Shares of MYOS RENS and Corcept Therapeutics were two biotech stocks seeing huge gains in Tuesday’s trading session. MYOS RENS shares soared after news of its product being launched with The Vitamin Shoppe. The fact that a generic version of Corcept Therapeutics’ Korlym drug may not happen for a while had traders cheering and sending the stock higher.
Tue, 11 Dec 2018
21:58:00 +0000
Here's Why Corcept Therapeutics Surged Today
It looks like generic versions of the company's Cushing syndrome treatment will hit a roadblock.
Tue, 11 Dec 2018
21:26:00 +0000
Here's Why Corcept Therapeutics Rose 18.6% in November
Solid revenue growth and pipeline progress from the biotech fueled the rise.
Fri, 30 Nov 2018
13:15:00 +0000
Report: Exploring Fundamental Drivers Behind Tesla, Nordson, Paycom Software, PDL BioPharma, Corcept Therapeutics, and Willis Towers Watson Public — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Mon, 26 Nov 2018
13:35:51 +0000
What You Must Know About Corcept Therapeutics Incorporated’s (NASDAQ:CORT) Financial Strength
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Corcept Therapeutics Incorporated (NASDAQ:CORT), as the company does not have to adhere to strict debt covenants. However, it also faces<div><a class="permalink" href="https://simplywall.st/news/yahoo-post/what-you-must-know-about-corcept-therapeutics-incorporateds-nasdaqcort-financial-strength/">Read More...</a></div>
Tue, 20 Nov 2018
21:24:09 +0000
Corcept Initiates Phase III Study for Cushing's Syndrome
Corcept (CORT) doses first patient in the phase III study of relacorilant for the treatment of Cushing's syndrome.
Mon, 19 Nov 2018
14:05:00 +0000
Corcept Therapeutics Announces First Patient Dosed in Phase 3 Trial of Relacorilant to Treat Patients with Cushing’s Syndrome
Corcept Therapeutics Incorporated (CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today announced that it dosed the first patient in the Phase 3 trial of relacorilant to treat patients with Cushing’s syndrome. The Phase 3 trial (entitled “GRACE”) is expected to enroll 130 patients with Cushing’s syndrome at sites in the United States, Canada and Europe.  The trial has a two-phase design.  In the initial, open-label portion, all patients will receive relacorilant for 22 weeks, with doses starting at 100 mg per day, then increasing in 100 mg increments, as clinically indicated, to a maximum of 400 mg per day.
Thu, 15 Nov 2018
02:46:14 +0000
Edited Transcript of CORT earnings conference call or presentation 1-Nov-18 9:00pm GMT
Q3 2018 Corcept Therapeutics Inc Earnings Call
Mon, 05 Nov 2018
19:25:07 +0000
Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates
Corcept (CORT) reports in-line earnings in the third quarter of 2018 and reaffirms its revenue guidance for 2018.
Fri, 02 Nov 2018
00:15:12 +0000
Corcept Therapeutics (CORT) Meets Q3 Earnings Estimates
Corcept (CORT) delivered earnings and revenue surprises of 0.00% and -4.10%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Thu, 01 Nov 2018
23:09:41 +0000
Corcept: 3Q Earnings Snapshot
The Menlo Park, California-based company said it had net income of 14 cents per share. Earnings, adjusted for stock option expense and non-recurring costs, were 22 cents per share. The drug developer posted ...
Thu, 01 Nov 2018
20:05:00 +0000
Corcept Therapeutics Announces Third Quarter 2018 Financial Results and Provides Corporate Update
MENLO PARK, Calif., Nov. 01, 2018 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat.
Wed, 31 Oct 2018
18:52:11 +0000
Is Corcept Therapeutics Incorporated’s (NASDAQ:CORT) CEO Incentives Align With Yours?
In 1999 Joseph Belanoff was appointed CEO of Corcept Therapeutics Incorporated (NASDAQ:CORT). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we’ll<div><a class="permalink" href="https://simplywall.st/news/yahoo-post/is-corcept-therapeutics-incorporateds-nasdaqcort-ceo-incentives-align-with-yours/">Read More...</a></div>
Thu, 25 Oct 2018
20:05:00 +0000
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Oct. 25, 2018 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its third quarter 2018 financial results and provide a.
Wed, 24 Oct 2018
12:05:00 +0000
Judge Denies Teva Pharmaceuticals’ Motion to Dismiss Corcept Therapeutics’ Allegations of Patent Infringement
MENLO PARK, Calif., Oct. 24, 2018 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat.
Tue, 23 Oct 2018
13:00:00 +0000
Report: Exploring Fundamental Drivers Behind Corcept Therapeutics, News Corporation, Nightstar Therapeutics PLC Sponsored ADR, Rudolph Technologies, Applied Optoelectronics, and United Rentals — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Thu, 04 Oct 2018
14:08:43 +0000
Should You Be Holding Corcept Therapeutics Incorporated (NASDAQ:CORT) Right Now?
Anyone researching Corcept Therapeutics Incorporated (NASDAQ:CORT) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory.<div><a class="permalink" href="https://simplywall.st/news/yahoo-post/should-you-be-holding-corcept-therapeutics-incorporated-nasdaqcort-right-now/">Read More...</a></div>
Mon, 01 Oct 2018
11:15:00 +0000
Corcept Therapeutics Receives Orphan Designation for Relacorilant as Treatment for Pancreatic Cancer
Corcept Therapeutics Incorporated (CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today announced that the Food and Drug Administration (FDA) has granted orphan drug status to Corcept’s selective cortisol modulator relacorilant to treat patients with pancreatic cancer. Corcept is conducting clinical trials of relacorilant in combination with nab-paclitaxel (Celgene Corporation’s drug, Abraxane®) as a treatment for pancreatic cancer and other solid tumors.
Wed, 12 Sep 2018
12:52:12 +0000
Do Options Traders Know Something About Corcept (CORT) Stock We Don't?
Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This site is a gem, and based on the posts by many members and my personal experience it is a site for learning, sharing and especially making money." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards